Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery

Documents similaires

• Why insulin aspart and insulin degludec exhibit distinct release mechanisms
  par: Zhuo Lin Li, et autres
  Publié: (2024)
• Sensor‐derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart—A secondary analysis of the CopenFast trial
  par: Julie C. Søholm, et autres
  Publié: (2024)
• Faster‐acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non‐automated insulin pump and continuous glucose monitoring—A double‐blind randomized controlled crossover trial
  par: Ajenthen G. Ranjan, et autres
  Publié: (2025)
• Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study
  par: Leili Gao, et autres
  Publié: (2025)
• Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?
  par: Kowalczyk‐Korcz Emilia, et autres
  Publié: (2026)